The affect of nasal delivery of an Interferon (IFN -1)/ Hyaluronic Acid formulation on the clinical course of COVID-19 infection determined by time to resolution of symptoms.[To be assessed via Total Nasal Symptom Score: The sum of 5 individual participant-assessed symptom scores using ordinal scales for each of the following symptoms: Sneezing; rhinorrhoea; nasal itching; nasal pain and nasal obstructionTimepoints: baseline (pre-randomisation); then 7 days; 2 weeks; 4 weeks post-randomisation];The affect of nasal delivery of an Interferon (IFN -1)/ Hyaluronic Acid formulation on viral clearance of COVID-19 infection[Determined by daily decline in viral load from Day 0 to Day 5: based on cycle threshold value from nasopharyngeal PCR. ]

The affect of nasal delivery of an Interferon (IFN -1)/ Hyaluronic Acid formulation on the clinical course of COVID-19 infection determined by time to resolution of symptoms.[To be assessed via Total Nasal Symptom Score: The sum of 5 individual participant-assessed symptom scores using ordinal scales for each of the following symptoms: Sneezing; rhinorrhoea; nasal itching; nasal pain and nasal obstructionTimepoints: baseline (pre-randomisation); then 7 days; 2 weeks; 4 weeks post-randomisation];The affect of nasal delivery of an Interferon (IFN -1)/ Hyaluronic Acid formulation on viral clearance of COVID-19 infection[Determined by daily decline in viral load from Day 0 to Day 5: based on cycle threshold value from nasopharyngeal PCR. ]